BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 23974956)

  • 1. MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphoma.
    Ying CY; Dominguez-Sola D; Fabi M; Lorenz IC; Hussein S; Bansal M; Califano A; Pasqualucci L; Basso K; Dalla-Favera R
    Nat Immunol; 2013 Oct; 14(10):1084-92. PubMed ID: 23974956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MEF2B is a member of the BCL6 gene transcriptional complex and induces its expression in diffuse large B-cell lymphoma of the germinal center B-cell-like type.
    El Jamal SM; Grada Z; El Dinali MH; Zhou H; Hassan SY; Saad AG; Gibson B; Zhou X; Abulsayen HA; Khadra HS; Friedman J; Shalaby H; Kadi A; Megahed M; Emberesh M; Teruya-Feldstein J; Firpo-Betancourt A; Haikel Y; Fraig M; Hassan M
    Lab Invest; 2019 Apr; 99(4):539-550. PubMed ID: 30446717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCL6--regulated by AhR/ARNT and wild-type MEF2B--drives expression of germinal center markers MYBL1 and LMO2.
    Ding J; Dirks WG; Ehrentraut S; Geffers R; MacLeod RA; Nagel S; Pommerenke C; Romani J; Scherr M; Vaas LA; Zaborski M; Drexler HG; Quentmeier H
    Haematologica; 2015 Jun; 100(6):801-9. PubMed ID: 25769544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Myocyte Enhancer Factor 2B Versus Other Germinal Center-associated Antigens in the Differential Diagnosis of B-Cell Non-Hodgkin Lymphomas.
    Moore EM; Swerdlow SH; Gibson SE
    Am J Surg Pathol; 2018 Mar; 42(3):342-350. PubMed ID: 29309299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma.
    Saito M; Novak U; Piovan E; Basso K; Sumazin P; Schneider C; Crespo M; Shen Q; Bhagat G; Califano A; Chadburn A; Pasqualucci L; Dalla-Favera R
    Proc Natl Acad Sci U S A; 2009 Jul; 106(27):11294-9. PubMed ID: 19549844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL.
    Ci W; Polo JM; Cerchietti L; Shaknovich R; Wang L; Yang SN; Ye K; Farinha P; Horsman DE; Gascoyne RD; Elemento O; Melnick A
    Blood; 2009 May; 113(22):5536-48. PubMed ID: 19307668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary mediastinal B-cell lymphoma: hypermutation of the BCL6 gene targets motifs different from those in diffuse large B-cell and follicular lymphomas.
    Malpeli G; Barbi S; Moore PS; Scardoni M; Chilosi M; Scarpa A; Menestrina F
    Haematologica; 2004 Sep; 89(9):1091-9. PubMed ID: 15377470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MEF2B Instructs Germinal Center Development and Acts as an Oncogene in B Cell Lymphomagenesis.
    Brescia P; Schneider C; Holmes AB; Shen Q; Hussein S; Pasqualucci L; Basso K; Dalla-Favera R
    Cancer Cell; 2018 Sep; 34(3):453-465.e9. PubMed ID: 30205047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma.
    Pasqualucci L; Migliazza A; Basso K; Houldsworth J; Chaganti RS; Dalla-Favera R
    Blood; 2003 Apr; 101(8):2914-23. PubMed ID: 12515714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma.
    Morin RD; Mendez-Lago M; Mungall AJ; Goya R; Mungall KL; Corbett RD; Johnson NA; Severson TM; Chiu R; Field M; Jackman S; Krzywinski M; Scott DW; Trinh DL; Tamura-Wells J; Li S; Firme MR; Rogic S; Griffith M; Chan S; Yakovenko O; Meyer IM; Zhao EY; Smailus D; Moksa M; Chittaranjan S; Rimsza L; Brooks-Wilson A; Spinelli JJ; Ben-Neriah S; Meissner B; Woolcock B; Boyle M; McDonald H; Tam A; Zhao Y; Delaney A; Zeng T; Tse K; Butterfield Y; Birol I; Holt R; Schein J; Horsman DE; Moore R; Jones SJ; Connors JM; Hirst M; Gascoyne RD; Marra MA
    Nature; 2011 Jul; 476(7360):298-303. PubMed ID: 21796119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms.
    Parekh S; Polo JM; Shaknovich R; Juszczynski P; Lev P; Ranuncolo SM; Yin Y; Klein U; Cattoretti G; Dalla Favera R; Shipp MA; Melnick A
    Blood; 2007 Sep; 110(6):2067-74. PubMed ID: 17545502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coexpression of Bcl-6 and CD10 in diffuse large B-cell lymphomas: significance of Bcl-6 expression patterns in identifying germinal center B-cell lymphoma.
    Ree HJ; Yang WI; Kim CW; Huh J; Lee SS; Cho EY; Ko YH; Charney D
    Hum Pathol; 2001 Sep; 32(9):954-62. PubMed ID: 11567225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.
    Morin RD; Johnson NA; Severson TM; Mungall AJ; An J; Goya R; Paul JE; Boyle M; Woolcock BW; Kuchenbauer F; Yap D; Humphries RK; Griffith OL; Shah S; Zhu H; Kimbara M; Shashkin P; Charlot JF; Tcherpakov M; Corbett R; Tam A; Varhol R; Smailus D; Moksa M; Zhao Y; Delaney A; Qian H; Birol I; Schein J; Moore R; Holt R; Horsman DE; Connors JM; Jones S; Aparicio S; Hirst M; Gascoyne RD; Marra MA
    Nat Genet; 2010 Feb; 42(2):181-5. PubMed ID: 20081860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PATZ1 expression correlates positively with BAX and negatively with BCL6 and survival in human diffuse large B cell lymphomas.
    Franco R; Scognamiglio G; Valentino E; Vitiello M; Luciano A; Palma G; Arra C; La Mantia E; Panico L; Tenneriello V; Pinto A; Frigeri F; Capobianco G; Botti G; Cerchia L; De Chiara A; Fedele M
    Oncotarget; 2016 Sep; 7(37):59158-59172. PubMed ID: 27494852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The BCL6-associated transcriptional co-repressor, MTA3, is selectively expressed by germinal centre B cells and lymphomas of putative germinal centre derivation.
    Jaye DL; Iqbal J; Fujita N; Geigerman CM; Li S; Karanam S; Fu K; Weisenburger DD; Chan WC; Moreno CS; Wade PA
    J Pathol; 2007 Sep; 213(1):106-15. PubMed ID: 17573669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MEF2B mutations in non-Hodgkin lymphoma dysregulate cell migration by decreasing MEF2B target gene activation.
    Pon JR; Wong J; Saberi S; Alder O; Moksa M; Grace Cheng SW; Morin GB; Hoodless PA; Hirst M; Marra MA
    Nat Commun; 2015 Aug; 6():7953. PubMed ID: 26245647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation Analysis Between the Expression of MEF2B, and Germinal Center and Nongerminal Center Markers in Diffuse Large B-Cell Lymphoma.
    Salama A; Marcellino BK; Saad AG; Teruya-Feldstein J; Firpo-Betancourt A; Abulsayen HA; Grada Z; Hassan M; El Jamal SM
    Appl Immunohistochem Mol Morphol; 2020 Aug; 28(7):e63-e64. PubMed ID: 31850910
    [No Abstract]   [Full Text] [Related]  

  • 18. Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas.
    Polo JM; Juszczynski P; Monti S; Cerchietti L; Ye K; Greally JM; Shipp M; Melnick A
    Proc Natl Acad Sci U S A; 2007 Feb; 104(9):3207-12. PubMed ID: 17360630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bcl-6 and Bcl-2 protein expression in diffuse large B-cell lymphoma and follicular lymphoma: correlation with 3q27 and 18q21 chromosomal abnormalities.
    Skinnider BF; Horsman DE; Dupuis B; Gascoyne RD
    Hum Pathol; 1999 Jul; 30(7):803-8. PubMed ID: 10414499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determining the Origin of Human Germinal Center B Cell-Derived Malignancies.
    Seifert M; Küppers R
    Methods Mol Biol; 2017; 1623():253-279. PubMed ID: 28589362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.